Trinity Biotech

Trinity Biotech Fixed Asset Turnover

The Fixed Asset Turnover of Trinity Biotech (TRIB) as of Nov 10, 2026 is 13.71. In the previous year, Fixed Asset Turnover was 11.93 — a change of 14.92% (higher).

Fixed Asset Turnover

13.71

YoY

14.92%

Last updated:

Fixed Asset Turnover of Trinity Biotech is 2021 13.71 . Fixed Asset Turnover of Trinity Biotech was 2020 11.93 . It decreases by 14.92% higher compared to the previous year.

The Trinity Biotech Fixed Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Fixed Asset Turnover
Date
Fixed Asset Turnover
Jan 1, 2014
5.87 USD
Jan 1, 2015
4.85 USD
Jan 1, 2016
7.43 USD
Jan 1, 2017
17.09 USD
Jan 1, 2018
18.10 USD
Jan 1, 2019
9.73 USD
Jan 1, 2020
11.93 USD
Jan 1, 2021
13.71 USD
The Trinity Biotech Fixed Asset Turnover history
YEARFixed Asset TurnoverYoY
13.71+14.92%
11.93+22.57%
9.73-46.21%
18.10+5.87%
17.09+129.99%
7.43+53.24%
4.85-17.32%
5.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Fixed Asset Turnover of Trinity Biotech is 13.71 in 2021.

Fixed Asset Turnover of Trinity Biotech changed from 11.93 to 13.71, representing a 14.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Fixed Asset Turnover Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Fixed asset turnover measures revenue generated per unit of PP&E. Higher ratios indicate more efficient utilization of physical assets.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Fixed Asset Turnover's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Fixed Asset Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Fixed Asset Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Trinity Biotech

All Key Metrics — Trinity Biotech